Drug intelligence / Profile preview

FC-122

Development stage: Preclinical
Modality: Small Molecules
Administration: Oral

Overview

FC-122 is a semisynthetic derivative of glycyrrhetinic acid (GA) that functions as a dual inhibitor of protein tyrosine phosphatase 1B (PTP1B) and alpha-glucosidase. Developed for the treatment of type 2 diabetes (T2D), it aims to address the disease through two distinct pathways: enhancing insulin sensitivity by inhibiting PTP1B and reducing the absorption of carbohydrates in the intestines by inhibiting alpha-glucosidase. Preclinical evaluations in streptozotocin-induced diabetic rat models have shown that FC-122 possesses significant anti-diabetic activity, surpassing the efficacy of the standard treatment acarbose, while maintaining a favorable safety profile in acute toxicity studies.

Other names: glycyrrhetinic acid derivative FC-122

Targets

Sucrase-IsomaltasePTPN1 (Protein tyrosine phosphatase 1B)

Beyond the preview

Go deeper on FC-122.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FC-122.

Explore the full profile